TTrialPathMatch Me to Trials
← Back to trials
RecruitingWeight Loss

Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)

Eligible age

18+ yrs

Accepts

All genders

Locations

16 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) adults with Type 2 Diabetes Mellitus.

Sponsor: Viking Therapeutics, Inc.

You may qualify if…

  • ✓ 1. Age ≥18 years of age at the time of signing the informed consent.
  • ✓ 2. Body mass index (BMI) ≥ 27 kg/m2
  • ✓ 3. Have Type 2 Diabetes Mellitus according to the American Diabetes Association (See Section 12.5), with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening. Participants with HbA1c between 6.5%-6.9% or 11.0%-11.5% are allowed to have a single HbA1c retesting to confirm eligibility. Type 2 Diabetes Mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists.

You may not qualify if…

  • ✕ 1. History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation
  • ✕ 2. Self-reported body weight change of 5% or more within 3 months of screening
  • ✕ 3. Have a prior or planned surgical treatment for obesity such as a gastric sleeve, lap band or any form of bariatric surgery (except for liposuction or abdominoplasty if performed \>1 year prior to screening)
  • ✕ 4. Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)
  • ✕ 5. Have Type 1 Diabetes Mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except Type 2 Diabetes Mellitus (T2DM)
  • ✕ 6. Have had 1 or more episodes of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months of screening
  • ✕ Note: Severe hypoglycemia episodes should be considered when severe cognitive impairment requiring the assistance of another person occurs and the administration of carbohydrate, glucagon, or other resuscitative actions are required. Blood glucose (BG) measurements may not be available during such an event, but neurological recovery attributable to the restoration of BG to normal is considered sufficient evidence that the event was induced by a low BG concentration. If BG measurements are available, the levels associated with severe hypoglycemia are BG \< 54 mg/dL.
  • ✕ 7. Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values \> 270 mg/dL (on 2 non-consecutive days) within 4 weeks prior to randomization

Where it's recruiting

Arizona

Tucson

California

Lake Forest

Florida

Ocoee

Georgia

Atlanta

Indiana

Evansville · Indianapolis · Valparaiso

Minnesota

Richfield

Missouri

Springfield

New Mexico

Albuquerque

New York

Binghamton

Oregon

Medford

Rhode Island

East Greenwich

Source: ClinicalTrials.gov · NCT07868939 · last updated 2026-11-16